Total Valuation
Fate Therapeutics has a market cap or net worth of €243.13M. The enterprise value is €246.98.
Market Cap€243.13M
Enterprise Value€246.98
Share Statistics
Fate Therapeutics has 119,820,510 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding119,820,510
Owned by Insiders12.42%
Owned by Institutions17.64%
Financial Efficiency
Fate Therapeutics’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -51.39%.
Return on Equity (ROE)-0.66
Return on Assets (ROA)-0.43
Return on Invested Capital (ROIC)-51.39%
Return on Capital Employed (ROCE)-0.52
Revenue Per Employee41.28K
Profits Per Employee-846.68K
Employee Count161
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Fate Therapeutics is ―. Fate Therapeutics’s PEG ratio is 0.03.
PE Ratio―
PS Ratio17.56
PB Ratio0.56
Price to Fair Value0.56
Price to FCF-1.04
Price to Operating Cash Flow-2.78
PEG Ratio0.03
Income Statement
In the last 12 months, Fate Therapeutics had revenue of 6.65M and earned -136.31M in profits. Earnings per share was -1.15.
Revenue6.65M
Gross Profit-6.25M
Operating Income-147.70M
Pretax Income-136.31M
Net Income-136.31M
EBITDA-127.02M
Earnings Per Share (EPS)-1.15
Cash Flow
In the last 12 months, operating cash flow was -101.94M and capital expenditures -3.71M, giving a free cash flow of -105.66M billion.
Operating Cash Flow-101.94M
Free Cash Flow-105.66M
Free Cash Flow per Share-0.88
Dividends & Yields
Fate Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.61
52-Week Price Change143.38%
50-Day Moving Average2.19
200-Day Moving Average1.49
Relative Strength Index (RSI)39.54
Average Volume (3m)4.00
Important Dates
Fate Therapeutics upcoming earnings date is Oct 29, 2026, TBA (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateOct 29, 2026
Ex-Dividend Date―
Financial Position
Fate Therapeutics as a current ratio of 5.79, with Debt / Equity ratio of 49.32%
Current Ratio5.79
Quick Ratio5.79
Debt to Market Cap0.63
Net Debt to EBITDA-0.25
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Fate Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Fate Therapeutics EV to EBITDA ratio is -1.16, with an EV/FCF ratio of -1.32.
EV to Sales22.26
EV to EBITDA-1.16
EV to Free Cash Flow-1.32
EV to Operating Cash Flow-1.39
Balance Sheet
Fate Therapeutics has €153.77M in cash and marketable securities with €75.67M in debt, giving a net cash position of €78.09M billion.
Cash & Marketable Securities€153.77M
Total Debt€75.67M
Net Cash€78.09M
Net Cash Per Share€0.65
Tangible Book Value Per Share€1.74
Margins
Gross margin is -343.01%, with operating margin of -2222.45%, and net profit margin of -2051.08%.
Gross Margin-343.01%
Operating Margin-2222.45%
Pretax Margin-2051.08%
Net Profit Margin-2051.08%
EBITDA Margin-1911.22%
EBIT Margin-2051.08%
Analyst Forecast
The average price target for Fate Therapeutics is €5.76, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€5.76
Price Target Upside172.98% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast-28.37%
EPS Growth Forecast32.58%